Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

468.72 -3.79 (-0.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,234,635
Open 473.21
Bid (Size) 469.00 (2)
Ask (Size) 477.00 (2)
Prev. Close 472.51
Today's Range 467.67 - 477.31
52wk Range 335.82 - 486.43
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
Growth stocks with wide moats and strong financials can compound investor returns with time. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
These healthcare stocks have clear paths to growth over the next few years. 
Via The Motley Fool

Performance

YTD
+14.07%
+14.07%
1 Month
+2.94%
+2.94%
3 Month
+11.47%
+11.47%
6 Month
+14.07%
+14.07%
1 Year
+34.86%
+34.86%

More News

Read More
2 Healthcare Stocks That Are Screaming Buys in June
Via The Motley Fool
You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
Via InvestorPlace
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX.
Via Chartmill
13 Analysts Have This To Say About Vertex Pharmaceuticals
Via Benzinga
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
Via The Motley Fool
3 Biotech Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
Via The Motley Fool
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)?
Via Chartmill
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
Via The Motley Fool
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
Via The Motley Fool
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
2 Healthcare Stocks to Buy Hand Over Fist in June
Via The Motley Fool
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Via Talk Markets
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Via The Motley Fool
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Via Benzinga
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.